KRAS and cancer: To evaluate efficacy of lymph-node targeted cancer vaccine ELI-002 2P in PDAC and colorectal cancer patients status-post surgery and locoregional therapy who are considered high-risk for recurrence based on alterations in ctDNA levels harboring G12D and G12R mutant KRAS